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Since most anti-arrhythmic drugs possess serious 
adverse effects, finding safer anti-arrhythmic agents 
with fewer side effects is very important. Statins are 
the main class of drugs, which used for management 
of hypercholesterolemia (Gagné et al., 2002). Studies 
have revealed that statins possess various additional 
beneficial cardioprotective properties against stroke, 
angina and thrombosis (Sever et al., 2003, Law et al., 
2003, Wilson et al., 1998, Furie, 2012). Pleiotropic 
effects of statins on arrhythmia have also been 
reported (Turagam et al., 2015) based on the 
mechanisms including the improvement of heart rate 
variability (Pehlivanidis et al., 2001), the reduction in 
corrected QT duration and QT variability (Vrtovec et 
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Abstract 
Introduction: Considering the cardioprotective and anti-inflammatory properties of 
statins, the aim of the present experiment was to investigate the possible involvement 
of inflammatory cytokines in anti-arrhythmic effects of rosuvastatin in both in vitro and 
in vivo experiments in rats. 
 
Methods: Three weeks after oral administration of either of rosuvastatin or vehicle, 
the atria were removed and after incubation with ouabain, time of onset of arrhythmia 
and asystole were recorded. We also used immunohistochemistry technique to 
identify the differentially expressed proteins interleukin (IL)-1β, IL-6 and tumor 
necrosis factor (TNF)-α in atria. 
 
Results: Rosuvastatin significantly postponed the onset of arrhythmia compared to 
vehicle-treated group. Injection of ouabain increased the atrial expression of IL-1β, IL-
6 and TNF-α proteins, while pretreatment of rats with rosuvastatin could significantly 
attenuate them. 
 
Conclusion: Our data suggest that rosuvastatin exerts anti-arrhythmic properties at 
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al., 2005) and the inhibition of ventricular late 
potentials (Kayikcioglu et al., 2003). Statins also 
diminish the risk of ventricular tachyarrhythmia and 
sudden cardiac death both in coronary artery disease 
and non-ischemic cardiomyopathy (Buber et al., 
2012, Dickinson et al., 2007, Bourne et al., 2010). In 
addition, statin therapy possesses a beneficial effect 
on aortic arterial stiffness (Upala et al., 2017) and 
could diminish the overall mortality, significantly 
(Nunes, 2017). Frequent experiments report that 
statins at high doses also have anti-inflammatory 
effects and improve endothelial function, which can 
stabilize and even regress plaques (Jain and Ridker, 
2005, Weitz-Schmidt, 2002, Diomede et al., 2001, 
Libby and Aikawa, 2003, Lima et al., 2004). On the 
other hand, evidence shows that inflammatory 
cytokines have a key role in occurrence of various 
cardiac arrhythmias (Marcus et al., 2010, Engelmann 
and Svendsen, 2005, Duncan et al., 2010). 
Ouabain is a  cardiac glycoside, which has positive 
inotropic effects and can improve the heart failure 









 exchanger and subsequent increase of 
intracellular calcium and myocardial contraction (Yu 
and Choi, 1997). Nevertheless, higher doses of 
ouabain represents an animal model for induction of 
cardiac arrhythmias. On the other hand, it has been 
reported that ouabain induces the production of 
proinflammatory cytokines (Matsumori et al., 2000). 
Since a majority of hyperlipidemic patients suffer from 
comorbid cardiovascular disorders including cardiac 
arrhythmias and considering the cardioprotective 
properties of statins, we previously reported that 
atorvastatin exerts marked anti-arrhythmic properties 
through diminution of inflammatory cytokines levels in 
atria (Najjari et al., 2018). Subsequently, in the 
present experiment, we aimed to detect the atrial 
immunostaining reactions of inflammatory cytokines 
in possible anti-arrhythmic properties of another drug 
of statin family, rosuvastatin in ouabain-induced 
arrhythmia in isolated rat atria. 
Materials and methods  
Animals 
Male Wistar albino rats weighting 200-230g were 
used. Rats were kept at the temperature of 22±2°C, 
humidity 80%, 12-h light/dark cycle (light on at 7am) 
and had ad libitum access to food and water. All 
experiments were conducted in Tehran University of 
Medical Sciences in accordance with the 
recommendations of the ethics committee on animal 
experimentation of the medical school (number IR. 
TUMS.MEDICINE.REC.1396.4132), which conforms 
to the provisions of the Declaration of Helsinki. 
 
Chemicals 
Salts for preparing physiological salt solution were 
purchased from Merck (Germany). Rosuvastatin, 
ouabain and 4′,6-diamidino-2-phenylindole (DAPI) 
were prepared from Sigma-Aldrich (USA) and 
immunohistochemical antibodies against interleukin 
(IL)-1β, IL-6 and tumor necrosis factor (TNF)-α  were 
purchased from Abcam (USA). 
 
Experimental groups 
In vitro experiment 
For isolated atria recording, 12 rats divided into two 
equal groups received either of 10mg/kg rosuvastatin 
dissolved in 1% carboxymethyl cellulose (CMC) in 
normal saline as vehicle or only 1% CMC in normal 
saline (Wallace et al., 2000), orally once daily for 3 
weeks. Rosuvastatin or CMC were administered by 
oral gavage in volume of 1ml/kg, once daily. In this 
procedure, a stainless steel bulb tipped gavage 
needle was attached to a syringe and used to deliver 
the compound into the stomach. 
 
In vivo experiment 
For immunohistochemical studies, 12 new rats 
different from the aforementioned rats were divided 
into three equal groups. The first and second groups 
received vehicle (1% CMC), while the third group was 
pretreated with rosuvastatin (10mg/kg in 1% CMC). 
Rosuvastatin or CMC were administered by oral 
gavage in volume of 1ml/kg, once daily for 3 weeks. 
From the days 19-21, the first group was injected by 
normal saline, whereas the second and third groups 
received injection of ouabain (0.56mg/kg) (Rodrigues-
Mascarenhas et al., 2006). All injections were in 
volume of 1ml/kg once daily for three consecutive 
days, intraperitoneally. 
 
Recording of isolated atria 
After anesthesia with ketamine (80mg/kg, Alfasan, 
Netherlands) and diazepam (2mg/kg, Caspian Tamin, 
Iran), the atria was rapidly removed and immersed in 
a tissue bath containing 20ml of carbogenated (95% 
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and pH 7.4 (Ghebleh Zadeh et al., 2018). The 
composition of the solution was as follows (mM): 
NaCl 112.0, KCl 5, CaCl2 1.8, MgCl2 1.0, NaH2PO4 
0.5, KH2PO4 0.5, NaHCO3 25.0, glucose 10.0 and 
EDTA 0.004 (Merck, Germany). After 30min 
equilibration under a preload tension of 1000mg, we 
recorded the onset time of arrhythmia (bigeminy) and 
asystole following incubation with ouabain (40µM) 
(Ghebleh Zadeh et al., 2018) as well as atrial beating 
rate and contractile force using isometric force 
transducer of PowerLab system (ADInstrument, 
Australia) and LabChart software. 
 
Immunohistochemistry 
Immunohistochemical study was carried out based on 
previous report (Cai and Wang, 2017). Briefly, 
paraffin sections of atrial tissue samples (5 micron 
thickness) were prepared. After dewaxed, tissue 
sections were washed in phosphate buffered saline 
(PBS, PH 7.4) for four times, followed by antigen 
retrieval by adding HCl 2 N (normal) for 30min. A 
primary antibody against IL-1β, IL-6 or TNF-α (1:100 
dilution) was added. After PBS wash, secondary 
antibody (Ab6785, Abcam, USA. 1:150 dilution) was 
added. Then, the fluorescent stain DAPI was added 
and examined under the fluorescent microscope 
(Olympus, Japan, 400X). The expression level was 
observed and analyzed in Image-pro plus system. 
Statistical analysis 
GraphPad Prism 5 software (San Diego, CA) was 
used for statistical analyses. Results are shown as 
mean±SEM. We used unpaired Student’s t-test to 
compare the onset time of arrhythmia and asystole 
and atrial beating rate and contractile force between 
treatment and control groups. We also used paired 
Student’s t-test to determine the effects of ouabain on 
atrial beating rate and contractile force within groups. 
One-way analysis of variance (ANOVA) followed by 
Tukey’s post-hoc test was carried out to compare the 
atrial expression of inflammatory cytokines between 
groups. P-values less than 0.05 were considered 
statistically significant. 
Results 
Recording of isolated atria 
Pretreatment of rats with rosuvastatin postponed the 
time of onset of arrhythmia (4.67min) compared to 
control vehicle-treated group (2.18min, P≤0.01). 
Although the time of onset of asystole in rosuvastatin-
treated group (9.27min) seems longer than control 
(6.95min), no statistically significant difference was 
detected between treatment and control groups 
(P>0.05, Fig. 1A). The difference in atrial beating rate 
between treatment (303.62 beat/min before, and 
significant (P>0.05, Fig. 1B). Similarly, there was no 
statistically significant difference between atrial 
Fig.1. Time of onset of arrhythmia and asystole (A), atrial beating rate (B) and atrial contractile force (C) after ouabain 
incubation in vehicle and rosuvastatin-treated groups. Data are shown as mean±SEM. Six rats were used in each group. 
**
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Fig.2. Chronotropic and inotropic pattern in vehicle and rosuvastatin-treated groups. In control group, ouabain-induced 
arrhythmia was strong (A), while the intensity of arrhythmia in rosuvastatin-treated group was diminished (B). The atrial 
beatings and contractile force prior incubation of ouabain were similar in both groups (C, D). Bigeminy arrhythmias (twin 
spikes with strong force), which is the typical manifestation of ouabain-induced arrhythmia were seen in control group (E), 
while in rosuvastatin-treated group, some small irregularities were recorded (F). The onset time of asystole in rosuvastatin-
treated group (H) was later than control group (G). 
Fig.3. Atrial levels of IL-1β (A), IL-6 (B) and TNF-α (C) in saline and ouabain-injected vehicle and rosuvastatin-treated 
groups. Data are shown as mean±SEM. Four rats were used in each group. 
****
P≤0.0001 compared to saline-injected 
vehicle-treated group; 
####
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contractile force of control (0.57g before, and 0.61g 
after ouabain incubation) and treatment (0.55g 
before, and 0.61g after ouabain incubation) groups 
(P>0.05, Fig.1C). Figure 2 compares the chronotropic 
and inotropic recording pattern in vehicle and 
rosuvastatin-treated groups. In control group, 
incubation of ouabain showed dramatic arrhythmias 
(Fig. 2A), while pretreatment of rats with rosuvastatin 
359.63 beat/min after ouabain incubation) and control 
(314.55 beat/min before, and 367.82 beat/min after 
Fig.4. Representative immunostaining of IL-1β in atrial tissue arrays of saline and ouabain-injected vehicle and 
rosuvastatin-treated groups. A: vehicle+ saline, positive reaction 10%. B: vehicle+ ouabain, positive reaction 75%. C: 
rosuvastatin+ ouabain, positive reaction 40%. I: nuclei stained by DAPI; II: primary antibody to IL-1β; III: merge. 
Magnification 400X.    
 
Fig.5. Representative immunostaining of IL-6 in atrial tissue arrays of saline and ouabain-injected vehicle and rosuvastatin-
treated groups. A: vehicle+ saline, positive reaction 7%. B: vehicle+ ouabain, positive reaction 75%. C: rosuvastatin+ 
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 ouabain incubation) groups was not statistically 
alleviated the intensity of arrhythmias (Fig. 2B). The 
shape of arrhythmia in control group was typical 
bigeminy (twin spikes with strong force, repeatedly), 
which is the common manifestation of ouabain-
induced arrhythmia (Fig. 2E). This arrhythmia lasted 
for several minutes and returned to the regular atrial 
rhythm in some samples. In rosuvastatin-treated 
group, irregularities between normal spikes were 




Injection of ouabain significantly boosted the atrial 
expression levels of all studied inflammatory 
cytokines (P≤0.0001). On the other hand, 
pretreatment of rats with rosuvastatin could attenuate 
them, significantly (P≤0.0001, Fig. 3). Figure 4 shows 
the representative immunostaining of IL-1β in atrial 
tissue arrays of saline and ouabain-injected vehicle 
and rosuvastatin-treated groups. The positive 
reaction in saline-injected vehicle-treated group was 
10%, while injection of ouabain elevated it to 75% 
and pretreatment of rats with rosuvastatin could 
significantly diminish it to 40%. Illustrating in Figure 5, 
the positive reaction for IL-6 in saline-injected vehicle-
treated group was only 7%, while injection of ouabain 
boosted it to 75% and pretreatment of rats with 
rosuvastatin could significantly attenuate it to 40%. 
Similarly, the positive reaction for TNF-α in saline-
injected vehicle-treated group was 10%, while 
injection of ouabain increased it to 75% and 
pretreatment of rats with rosuvastatin could 
significantly decrease it to 40% (Fig. 6). 
Discussion 
In the present experiment, we studied the 
involvement of inflammatory cytokines in anti-
arrhythmic effects of rosuvastatin in both in vitro and 
in vivo examinations in rats. Results showed that 
administration of rosuvastatin delayed the onset of 
ouabain-induced arrhythmia. Furthermore, 
rosuvastatin attenuated the ouabain-induced over-
expression of inflammatory cytokines. 
Evidence show that ouabain boosts the production of 
pro-inflammatory cytokines (Chung et al., 2001, Vila 
et al., 2000, Vasan et al., 2003). For example, 
Matsumori et al. (2000) have reported that incubation 
of ouabain increases the levels of IL-1α, IL-1β, IL-6 
and TNF-α in cultured human peripheral blood 
mononuclear cells. We also previously showed that 
ouabain could trigger the production of inflammatory 
Fig.6. Representative immunostaining of TNF-α in atrial tissue arrays of saline and ouabain-injected vehicle and 
rosuvastatin-treated groups. A: vehicle+ saline, positive reaction 10%. B: vehicle+ ouabain, positive reaction 75%. C: 
rosuvastatin+ ouabain, positive reaction 40%. I: nuclei stained by DAPI; II: primary antibody to TNF-α; III: merge. 
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cytokines in rat atria (Tokazzabani Belasi et al., 2018, 
Najjari et al., 2018, Moradi et al., 2016). It is also 
reported that atrial fibrillation increases the production 
of IL-6 in patients (Ishida, 2006). Our data are in 
agreement with the aforementioned experiments. 
Besides, we also showed that rosuvastatin attenuates 
the over-production of inflammatory cytokines 
following ouabain injection, which corroborates our 
previous experiment on atorvastatin (Najjari et al., 
2018). 
The metabolic syndrome can be associated with 
increased risk of atrial fibrillation and other cardiac 
arrhythmias (Watanabe et al., 2008). Statins exert 
their anti-arrhythmic properties through reduction in 
corrected QT duration, inhibition of ventricular late 
potentials and improvement of heart rate variability 
(Pehlivanidis et al., 2001, Vrtovec et al., 2005, 
Kayikcioglu et al., 2003). Perioperative statin therapy 
is a therapeutic strategy for prevention of 
postoperative atrial fibrillation via inhibiting the 
inflammatory pathways (Sanchez-Quinones et al., 
2008). Statins possess beneficial effects in acute 
myocardial infarction (Sicard et al., 2007, Baigent et 
al., 2008, Lenderink et al., 2006). The American heart 
association, American college of cardiology and 
European society of cardiology all suggest that 
statins should be prescribed following acute 
myocardial infarction (O'gara et al., 2013). 
A recent clinical trial study in 2018 compared the 
effects of hydrophilic rosuvastatin and lipophilic 
atorvastatin on nonsustained ventricular tachycardia. 
They suggested that the effects of rosuvastatin on 
nonsustained ventricular tachycardia might be better 
than that of atorvastatin (Hu et al., 2018). Evidence 
show that adverse events of statins are dose-
dependent (Jones et al., 2003). Given that a lower 
dose of rosuvastatin has a similar effect to higher 
doses of other statins, it is beneficial to use it (Guo et 
al., 2017). A high-dose of rosuvastatin can postpone 
ventricular remodeling, effectively suppress malignant 
remodeling of the heart, improve left ventricular 
systolic function, diminish the prevalence of adverse 
events and significantly improve the long-term 
prognosis (Guo et al., 2017). 
Numerous experiments have reported the anti-
inflammatory effects of statin (Blanco-Colio et al., 
2003, S Antonopoulos et al., 2012, Mehrzadi et al., 
2015). Inflammatory cytokines play a dramatic role in 
various pathological disorders. For example, London 
et al. (2003) have reported that TNF-α triggers the 
incidence of various atrial and ventricular 
arrhythmias. There are also other experiments 
indicating the involvement of TNF-α in 
pathophysiology of ventricular arrhythmia 
(Kowalewski et al., 2002, Duncan et al., 2010). 
Similarly, in the present experiment, our results are in 
agreement with the aforementioned reports indicating 
the anti-inflammatory properties of rosuvastatin. 
Moreover, various clinical trials report a marked 
correlation between atrial fibrillation and high levels of 
IL-6 (Ishida, 2006, Psychari et al., 2005, Wu et al., 
2013). The ouabain-induced over-expression of IL-6 
in our study also confirms the previous experiment. 
Clinical practice guidelines suggest that 
cardiovascular benefits of statins generally outweigh 
non-cardiovascular adverse effects in patients 
suffering from cardiovascular disorders (Desai et al., 
2014). The potentials of diverse therapeutic 
indications of statins could introduce the novel 
applications of this class of drugs in the future.  
Conclusion 
Our data suggest that rosuvastatin possesses anti-
arrhythmic properties and diminution of atrial 
inflammatory cytokines expression might at least in 
part explain this response. Possible other 
mechanisms for anti-arrhythmic effects of 
rosuvastatin need for further experiments. 
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